September 26, 2013 — Siemens’ PETNET Solutions has announced a three-year agreement with The US Oncology Network to supply its entire portfolio of Food and Drug Administration (FDA)-approved positron emission tomography (PET) radiopharmaceutical agents at each of PETNET Solutions’ current Good Manufacturing Practices (cGMP)-certified locations throughout the United States.
The US Oncology Network is one of the nation’s largest networks of community-based oncology physicians, conducting roughly 60,000 PET scans annually. This agreement also extends to community practices engaged in McKesson Specialty Health’s Onmark Select Program.
Under the agreement, Siemens’ PETNET Solutions also will provide The US Oncology Network-affiliated practices and Onmark Select Practices with its comprehensive portfolio of products and services to expand patient access to premium PET imaging services.
PET/CT imaging also plays a major role in the evaluation and treatment monitoring of cancer patients. The high contrast and sharp delineation of molecular resolution made possible through PET imaging is vital for tumor identification and treatment, enabling physicians to determine whether cancer is present, whether it has metastasized and whether treatment is effective. Because PET imaging measures molecular activity, it can accurately characterize a tumor’s malignant or benign state as well as confirm metastasis – enabling proper staging and facilitating suitable treatment protocols.
Siemens’ PETNET Solutions provides patient access to radiopharmaceuticals for the evaluation of cancer through PET. McKesson Specialty Health and Siemens’ PETNET Solutions share a common vision of expanding patient access to PET imaging services for cancer patients.
For more information: www.usa.siemens.com/healthcare